The clinical trial, which enrolled 41 patients with Parkinson’s Disease, was funded by Parkinson’s UK with support from The Cure Parkinson’s Trust and in association with the North The post GDNF trial yields promising results for treatment of Parkinson’s Disease appeared first on Pharmaceutical Business review.
Fri Mar 01, 2019 14:33
Maze Therapeutics has secured an initial investment commitment of $191m, led by Third Rock Ventures and ARCH Venture Partners. GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and The post Maze Therapeutics launches with $191m financing appeared first on Pharmaceutical Business review.
Fri Mar 01, 2019 10:30
This new treatment includes the same monoclonal antibody as intravenous Herceptin® (trastuzumab) in combination with recombinant human hyaluronidase PH20, an enzyme that helps to deliver trastuzumab under the The post FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers appeared first on Pharmaceutical Business review.
Fri Mar 01, 2019 10:30
The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent The post Horizon’s phase 3 trial for Teprotumumab in active thyroid eye disease meets primary endpoint appeared first on Pharmaceutical Business review.
Fri Mar 01, 2019 10:30
スイス・ヌーシャテル--(BUSINESS WIRE)--（ビジネスワイヤ） -- マシモ（NASDAQ: MASI）は本日、カナダ麻酔学会誌（Canadian Journal of Anesthesiology）に最近掲載された4件の症例から成るケースシリーズ研究の結果を発表しました。この研究でモントリオール大学の研究者らは、Masimo SedLine®脳機能モニタリングとO3®リージョナルオキシメトリーの併用が、心臓手術中における脳酸素飽和度低下の認識・管理に役立つことを発見しました。 Etienne Couture、Alain Deschamps、André Denaultの各ドクターらは、Masimo O3近赤外線分光法（NIRS）に基づいて先に開発された臨床管理アルゴリズムに、Masimo SedLineの脳波記録（EEG）信号処理パラメーターである患者状態指標（PSi）を使用した処理済みEEG信号（pEEG）を追加することで、脳酸素飽和度低下エピソードを管理するための指針を提供する上で役立つと仮定しました。本ケースシリーズ研究で各ドクターは、これら計測手法の組み合わせが
Fri Mar 01, 2019 03:52
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) annonce que sept abstracts tirés de son portefeuille de recherche sur le cancer seront présentés lors du prochain congrès annuel de l'American Association for Cancer Research (AACR). Le congrès se tiendra du 29 mars au 3 avril 2019, au Georgia World Congress Center, à Atlanta, dans l'état de Géorgie. Les abstracts acceptés comprennent des données issues d'études cliniques sur l'anticorps monoclonal anti-PD-1 d'Incyte, INCMG
Fri Mar 01, 2019 00:38
WILMINGTON, Del.--(BUSINESS WIRE)--Wie Incyte Corporation (Nasdaq:INCY) bekanntgibt, werden auf der bevorstehenden Jahreskonferenz 2019 der American Association for Cancer Research (AACR) sieben Abstracts mit Daten aus dem Krebsforschungsportfolio des Unternehmens vorgestellt. Die Konferenz findet vom 29. März – 3. April 2019 im Georgia World Congress Center in Atlanta, Georgia, USA, statt. Die bewilligten Abstracts enthalten Daten aus klinischen Studien, darunter der Anti-PD-1-monoklonale Anti
Fri Mar 01, 2019 00:09
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018. Fourth-quarter 2018 net sales were $617.5 million, a decrease of 0.6 percent compared to $621.3 million reported for the fourth quarter of 2017. On a currency-neutral basis, quarterly sales increased 1.9 percent compared to the same period in 2
Thu Feb 28, 2019 23:38
ROCKVILLE, Md.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/allergies?src=hash" target="_blank"gt;#allergieslt;/agt;--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held in Atlanta, Georgia from March 29-April 3, 2019. The poster will be presented during the meeting in a late-breaking poster session with preclinical data relating to Immunomic’s investigational...
Thu Feb 28, 2019 23:05
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and related conditions, today announced fourth quarter and full year 2018 financial results. “We are pleased with our fourth quarter performance, capping a year of strong, consistent revenue growth,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “We are successfully building scalable infrastructure across the entire organization, positioning the co
Thu Feb 28, 2019 23:02
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2018. “Last year was one of exceptional progress for Aimmune on multiple fronts as we advance AR101 to potentially be the first approved treatment for peanut allergy,” said Jayson Dallas, M.D., President and CEO of Aimmune. “In addition, we are on track to apply
Thu Feb 28, 2019 23:01
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important
Thu Feb 28, 2019 23:00
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) kondigt aan dat zeven abstracts met gegevens uit haar kankeronderzoekportfolio zullen worden gepresenteerd op de komende jaarlijkse bijeenkomst van de American Association for Cancer Research (AACR) 2019. De bijeenkomst vindt plaats van 29 maart t/m 3 april 2019 in het Georgia World Congress Center in Atlanta, Georgia. De geaccepteerde abstracts bevatten gegevens uit klinische onderzoeken met Incyte's anti-PD-1 monoklonaal ant
Thu Feb 28, 2019 22:50
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) annuncia la presentazione di sette abstract sui dati del suo portafoglio di studi per la ricerca sui tumori al congresso annuale 2019 dell'American Association for Cancer Research (AACR), che si svolgerà dal 29 marzo al 3 aprile 2019 al Georgia World Congress Center di Atlanta, in Georgia. Gli abstract accettati illustreranno dati di studi clinici sull'anticorpo monoclonale anti PD-1 di Incyte, INCMGA00121 nei pazienti con tumo
Thu Feb 28, 2019 22:50
CRANBURY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/DIP2019?src=hash" target="_blank"gt;#DIP2019lt;/agt;--Pharmacy Times Continuing Education™ to Host Directions in Pharmacy® Conference in Chicago
Thu Feb 28, 2019 22:33
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου